Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study.
Alexander A NavariniJörg C PrinzAkimichi MoritaTsen Fang TsaiManuelle-Anne ViguierLing LiChristian ThomaMogana SivalingamMark G LebwohlPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Patients with a GPP flare treated with spesolimab achieved improvements in PROs by Week 1, which were sustained for 12 weeks, and achieved MCIDs as early as Week 1.